Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Drug development involves a deep understanding of the mechanisms of action and possible side effects of each drug, and sometimes results in the identification of new and unexpected uses for drugs, termed as drug repurposing. Both in case of serendipitous observations and systematic mechanistic explorations, confirmation of new indications for a drug requires hypothesis building around relevant drug-related data, such as molecular targets involved, and patient and cellular responses. These datasets are available in public repositories, but apart from sifting through the sheer amount of data imposing computational bottleneck, a major challenge is the difficulty in selecting which databases to use from an increasingly large number of available databases. The database selection is made harder by the lack of an overview of the types of data offered in each database. In order to alleviate these problems and to guide the end user through the drug repurposing efforts, we provide here a survey of 102 of the most promising and drug-relevant databases reported to date. We summarize the target coverage and types of data available in each database and provide several examples of how multi-database exploration can facilitate drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077 · cited 5×
“Among pathway databases, KEGG [85] is one of the most comprehensive and nonredundant database (0.”
MethodInfluentialKEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“[10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
MethodRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 2×
“Addition of PPI data from STRING [72] D ow nloaded from https://academ ic.oup.com /bib/advance-article-abstract/doi/10.1093/bib/bbaa003/5735620 by guest on 11 M arch 2020 generated a new method, termed HNMDRP, that outperformed several state-of-the-art machine learning-based methods in correctly correlating responses…”
MethodInfluentialNCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865 · cited 4×
“Hence, we assigned ‘Pathways’ as primary subcategory for KEGG, which is listed under the main category ‘biomolecular’, as shown in Table 2.”
BackgroundInfluentialThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 7×
“Transcriptomic and drug response data in databases, such as GDA, CCLE and GDSC, can be correlated to reveal drug mechanisms.”
MethodInfluentialUniProt: the Universal Protein knowledgebase
Apweiler, R. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh131 · Cited by 7,498
O'Leary, N. A., Wright, M. W., Brister, J. R., Ciufo, S., Haddad, D., McVeigh, R., Rajput, B., Robbertse, B., Smith-White, B., Ako-Adjei, D., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1189 · Cited by 6,357
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
The GeneCards suite: from gene data mining to disease genome sequence analyses
Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., et al. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.5 · Cited by 5,550
UniProt: a hub for protein information
The UniProt Consortium (2015) · Nucleic Acids Research · doi:10.1093/nar/gku989 · Cited by 5,106
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · cited 1×
“This has created opportunities to assess the potential for new drug uses even before the experimental testing, which has proven particularly attractive for orphan diseases, in which traditional drug development is limited [16, 17].”
BackgroundThe Pfam protein families database in 2019
El-Gebali, S., Mistry, J., Bateman, A., Eddy, S. R., Luciani, A., Potter, S. C., Qureshi, M., Richardson, L. J., Salazar, G. A., Smart, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky995 · Cited by 4,602
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Daina, A., Michielin, O., & Zoete, V. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz382 · Cited by 4,534
UniProt: the universal protein knowledgebase
The UniProt Consortium (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1099 · Cited by 4,436 · cited 2×
“Among the proteomics databases, UniProt [118] could be the one choice as it integrates a wide variety of data types, such as pathways, protein-protein interactions (PPI), molecular omics, protein sequences, structures, classification and protein disease associations, as shown in Figure 1.”
BackgroundDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 3×
“A recent study introduced CDRscan, an algorithm that incorporates drug response assay data from GDSC, genomic data from CCLE and virtual docking based on structural fingerprints, including quantitative structure activity relationships (QSAR) information from DrugBank [145].”
BackgroundThe SWISS-PROT protein sequence data bank and its supplement TrEMBL
Bairoch, A., & Apweiler, R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.1.31 · Cited by 3,587
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“expansion and is a central drug development strategy for the pharmaceutical industry to ensure revenue as the average cost of developing a drug from scratch ranges from 1 to 2 billion dollars [2, 3], while drugs granted extended uses mainly incur only the regulatory and administrative costs.”
BackgroundA Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Human Protein Reference Database--2009 update
Keshava Prasad, T. S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., Telikicherla, D., Raju, R., Shafreen, B., Venugopal, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn892 · Cited by 3,234
Mi, H., Muruganujan, A., Ebert, D., Huang, X., & Thomas, P. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1038 · Cited by 3,033
The Reactome Pathway Knowledgebase
Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., Haw, R., Jassal, B., Korninger, F., May, B., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1132 · Cited by 2,855
Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F., & Hamosh, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1205 · Cited by 2,691
Piñero, J., Bravo, À., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., García-García, J., Sanz, F., & Furlong, L. I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw943 · Cited by 2,680 · cited 5×
“DisGeNET, additionally, has associated protein variants with human diseases.”
BackgroundMethodInfluentialA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330 · cited 3×
“Drug target interaction databases Among bioactivity or drug target interactions databases, PubChem [120] and ChEMBL [95] could be the databases of choice as these contain enormous nonredundant bioactivity datasets with more than 15 million curated bioactivities.”
BackgroundThe Database of Interacting Proteins: 2004 update
Salwinski, L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh086 · Cited by 2,271
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · cited 7×
“Transcriptomic and drug response data in databases, such as GDA, CCLE and GDSC, can be correlated to reveal drug mechanisms.”
MethodInfluentialCOSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922 · cited 1×
“If someone is specifically interested in cancer biomarkers, COSMIC [109] could be a good choice as it contains comprehensive and curated list of somatic mutations associated with different cancers, as shown in Table 4.”
BackgroundThe MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases
Orchard, S., Ammari, M., Aranda, B., Breuza, L., Briganti, L., Broackes-Carter, F., Campbell, N. H., Chavali, G., Chen, C., del-Toro, N., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1115 · Cited by 1,831
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 2×
“Similarly, kinase inhibitor imatinib was developed and first approved to target BCR-ABL in CML but was later was found to be effective in targeting KIT in gastrointestinal stromal tumors (GIST) [6].”
BackgroundSTITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data
Szklarczyk, D., Santos, A., von Mering, C., Jensen, L. J., Bork, P., & Kuhn, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1277 · Cited by 1,687 · cited 2×
“DTP is based on curated bioactivates whereas STITCH combines bioactivities with predicted compound target interactions using a weighted mechanism.”
BackgroundGilson, M. K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L., & Chong, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1072 · Cited by 1,628
UniRef: comprehensive and non-redundant UniProt reference clusters
Suzek, B. E., Huang, H., McGarvey, P., Mazumder, R., & Wu, C. H. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm098 · Cited by 1,613
The BioGRID interaction database: 2019 update
Oughtred, R., Stark, C., Breitkreutz, B.-J., Rust, J., Boucher, L., Chang, C., Kolas, N., O’Donnell, L., Leung, G., McAdam, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1079 · Cited by 1,473 · cited 3×
“Among PPI databases, BioGRID [66] could be used as it contains 1.”
MethodInfluentialThe SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451 · cited 2×
“A subset of Drug B that has significant correlation with Drug A is proceeded to the next step where we need to check side effects for ⊂Drug B using Sider database [116].”
BackgroundFunctional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,303
OPM: Orientations of Proteins in Membranes database
Lomize, M. A., Lomize, A. L., Pogozheva, I. D., & Mosberg, H. I. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btk023 · Cited by 1,173
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
MINT, the molecular interaction database: 2012 update
Licata, L., Briganti, L., Peluso, D., Perfetto, L., Iannuccelli, M., Galeota, E., Sacco, F., Palma, A., Nardozza, A. P., Santonico, E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr930 · Cited by 1,061
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022 · cited 1×
“[24] have recently provided an extensive review on the use of artificial intelligence for drug repurposing.”
BackgroundThe Comparative Toxicogenomics Database: update 2019
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky868 · Cited by 976
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B., Cheah, J. H., Adams, D. J., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V. L., Bodycombe, N. E., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 898 · cited 1×
“Subsequently, the anti-cancer potency of ML239 was demonstrated to be reduced in the cells knocked out for FADS2 or simultaneously treated with FADS2 inhibitor [132, 133].”
BackgroundThe MetaCyc database of metabolic pathways and enzymes
Caspi, R., Billington, R., Fulcher, C. A., Keseler, I. M., Kothari, A., Krummenacker, M., Latendresse, M., Midford, P. E., Ong, Q., Ong, W. K., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx935 · Cited by 894
Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887
Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818 · cited 2×
“Other examples include anti-inflammatory asthma medication montelukast, which was found to bind dipeptidyl peptidase IV [128], a promising drug target in type II diabetes.”
BackgroundHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807 · cited 1×
“However, it displays anti-cancer effects which are still incompletely understood and are at least independent of the ALDH-inhibitory function and associated with protein accumulation of nuclear protein NPL4 in a copperdependent fashion [130].”
BackgroundBenson, D. A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Ostell, J., Pruitt, K. D., & Sayers, E. W. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1094 · Cited by 760
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
ArrayExpress update—simplifying data submissions
Kolesnikov, N., Hastings, E., Keays, M., Melnichuk, O., Tang, Y. A., Williams, E., Dylag, M., Kurbatova, N., Brandizi, M., Burdett, T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1057 · Cited by 698
Wang, Y., Bryant, S. H., Cheng, T., Wang, J., Gindulyte, A., Shoemaker, B. A., Thiessen, P. A., He, S., & Zhang, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1118 · Cited by 671
A comprehensive transcriptional portrait of human cancer cell lines
Klijn, C., Durinck, S., Stawiski, E. W., Haverty, P. M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3080 · Cited by 660
International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data
Zhang, J., Baran, J., Cros, A., Guberman, J. M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., et al. (2011) · Database · doi:10.1093/database/bar026 · Cited by 638
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13877 · Cited by 597
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Brent, S., Chen, Y., Clapham, P., Coates, G., Fairley, S., Fitzgerald, S., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1064 · Cited by 594
(2014) · Nucleic Acids Research · doi:10.1093/nar/gku001 · Cited by 577
Sildenafil, a novel effective oral therapy for male erectile dysfunction
Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J. (1996) · British Journal of Urology · doi:10.1046/j.1464-410x.1996.10220.x · Cited by 564 · cited 1×
“An example of this type of repositioning is Sildenafil (Viagra), which failed to meet its primary endpoints in angina pectoris and hypertension, but instead is very successful as a medicine for erectile dysfunction [8].”
BackgroundA survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555 · cited 1×
“[22] have summarized recent progress in computational drug repositioning into four parts: repositioning strategies, computational approaches, validation methods and application areas.”
BackgroundGPCRdb in 2018: adding GPCR structure models and ligands
Pándy-Szekeres, G., Munk, C., Tsonkov, T. M., Mordalski, S., Harpsøe, K., Hauser, A. S., Bojarski, A. J., & Gloriam, D. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1109 · Cited by 553
Network-based approach to prediction and population-based validation of in silico drug repurposing
Cheng, F., Desai, R. J., Handy, D. E., Wang, R., Schneeweiss, S., Barabási, A.-L., & Loscalzo, J. (2018) · Nature Communications · doi:10.1038/s41467-018-05116-5 · Cited by 552
The MIPS mammalian protein–protein interaction database
Pagel, P., Kovac, S., Oesterheld, M., Brauner, B., Dunger-Kaltenbach, I., Frishman, G., Montrone, C., Mark, P., Stümpflen, V., Mewes, H.-W., et al. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti115 · Cited by 540
Petryszak, R., Keays, M., Tang, Y. A., Fonseca, N. A., Barrera, E., Burdett, T., Füllgrabe, A., Fuentes, A. M.-P., Jupp, S., Koskinen, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1045 · Cited by 530
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524 · cited 1×
“[19] have published a review on computational methods for drug repositioning and classified the methodologies either as drug or diseasebased repositioning.”
MethodCancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
Tamborero, D., Rubio-Perez, C., Deu-Pons, J., Schroeder, M. P., Vivancos, A., Rovira, A., Tusquets, I., Albanell, J., Rodon, J., Tabernero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0531-8 · Cited by 519
Open Targets Platform: new developments and updates two years on
Carvalho-Silva, D., Pierleoni, A., Pignatelli, M., Ong, C., Fumis, L., Karamanis, N., Carmona, M., Faulconbridge, A., Hercules, A., McAuley, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1133 · Cited by 472 · cited 2×
“Disease databases OpenTargets [108] and DisGeNET [34] are the most comprehensive databases when it comes to protein and disease associations, both having information on >17K proteins and >10K diseases.”
BackgroundPharmGKB: the Pharmacogenetics Knowledge Base
Hewett, M. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.163 · Cited by 428
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416 · cited 1×
“[20], have linked existing drugrepositioning methods with their integrated biological and pharmaceutical knowledge and have discussed how to customize a new drug-repositioning pipeline for specific studies.”
BackgroundDGIdb 2.0: mining clinically relevant drug–gene interactions
Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413
Gaedigk, A., Ingelman‐Sundberg, M., Miller, N. A., Leeder, J. S., Whirl‐Carrillo, M., Klein, T. E., & the PharmVar Steering Committee (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.910 · Cited by 409
OrthoDB: a hierarchical catalog of animal, fungal and bacterial orthologs
Waterhouse, R. M., Tegenfeldt, F., Li, J., Zdobnov, E. M., & Kriventseva, E. V. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1116 · Cited by 387
Machine learning and integrative analysis of biomedical big data
Mirza, B., Wang, W., Wang, J., Choi, H., Chung, N. C., & Ping, P. (2019) · Genes · doi:10.3390/genes10020087 · Cited by 380
Yu, C., Mannan, A. M., Yvone, G. M., Ross, K. N., Zhang, Y.-L., Marton, M. A., Taylor, B. R., Crenshaw, A., Gould, J. Z., Tamayo, P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3460 · Cited by 362
The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
Roth, B. L., Lopez, E., Patel, S., & Kroeze, W. K. (2000) · The Neuroscientist · doi:10.1177/107385840000600408 · Cited by 358
The vertebrate genome annotation (Vega) database
Wilming, L. G., Gilbert, J. G. R., Howe, K., Trevanion, S., Hubbard, T., & Harrow, J. L. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm987 · Cited by 351
PINA v2.0: mining interactome modules
Cowley, M. J., Pinese, M., Kassahn, K. S., Waddell, N., Pearson, J. V., Grimmond, S. M., Biankin, A. V., Hautaniemi, S., & Wu, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr967 · Cited by 350
Recent advances in computer-aided drug design
Song, C. M., Lim, S. J., & Tong, J. C. (2009) · Briefings in Bioinformatics · doi:10.1093/bib/bbp023 · Cited by 344
Cancer drug discovery by repurposing: teaching new tricks to old dogs
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.06.005 · Cited by 340 · cited 1×
“Other examples of such drug repositioning include cancer drugs crizotinib, sorafenib, azacitidine and decitabine, all of which failed to reach the markets in their original indications, yet now are important tools in the treatment of other types of cancers [9].”
BackgroundA review of network-based approaches to drug repositioning
Lotfi Shahreza, M., Ghadiri, N., Mousavi, S. R., Varshosaz, J., & Green, J. R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbx017 · Cited by 330
PDBe: Protein Data Bank in Europe
Velankar, S., Best, C., Beuth, B., Boutselakis, C. H., Cobley, N., Sousa Da Silva, A. W., Dimitropoulos, D., Golovin, A., Hirshberg, M., John, M., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp916 · Cited by 329
The Stanford Microarray Database: data access and quality assessment tools
Gollub, J. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg078 · Cited by 327
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Drug repositioning and repurposing: terminology and definitions in literature
Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.001 · Cited by 323 · cited 1×
“Apart from drug repositioning and utility extension, in many cases, a distinction can be made for drug development repositioning (sometimes called drug rescue), where a drug candidate developed for a certain indication fails but ends up being used for a different indication [7].”
BackgroundComprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
Chang, Y., Park, H., Yang, H.-J., Lee, S., Lee, K.-Y., Kim, T. S., Jung, J., & Shin, J.-M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27214-6 · Cited by 320
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · cited 1×
“Later on, it was known to possess affinity toward FYN kinase and was proceeded to Phase II testing for Alzheimer’s disease, in which FYN plays an important pathogenic role [126, 127].”
BackgroundA standard database for drug repositioning
Brown, A. S., & Patel, C. J. (2017) · Scientific Data · doi:10.1038/sdata.2017.29 · Cited by 305
Identification of Direct Protein Targets of Small Molecules
Lomenick, B., Olsen, R. W., & Huang, J. (2011) · ACS Chemical Biology · doi:10.1021/cb100294v · Cited by 299
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
Alexander, S. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Buneman, O. P., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13882 · Cited by 299
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters
Alexander, S. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13883 · Cited by 285
Wang, Y., Suzek, T., Zhang, J., Wang, J., He, S., Cheng, T., Shoemaker, B. A., Gindulyte, A., & Bryant, S. H. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt978 · Cited by 284
Pharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279
Yang, H., Qin, C., Li, Y. H., Tao, L., Zhou, J., Yu, C. Y., Xu, F., Chen, Z., Zhu, F., & Chen, Y. Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1230 · Cited by 270
DrugComb: an integrative cancer drug combination data portal
Zagidullin, B., Aldahdooh, J., Zheng, S., Wang, W., Wang, Y., Saad, J., Malyutina, A., Jafari, M., Tanoli, Z., Pessia, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz337 · Cited by 263 · cited 7×
“We also highlight several new databases that have not been previously covered in any review (e.g. [10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
BackgroundMethodInfluentialSelf-citationBragin, E., Chatzimichali, E. A., Wright, C. F., Hurles, M. E., Firth, H. V., Bevan, A. P., & Swaminathan, G. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt937 · Cited by 233
Liu, H., Zhang, W., Zou, B., Wang, J., Deng, Y., & Deng, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1007 · Cited by 230 · cited 2×
“Among drug combination databases, DrugComb [29] and DrugCombDB [37] provide qualitative drug combination responses in terms of sensitivity and synergy measures.”
BackgroundInference of immune cell composition on the expression profiles of mouse tissue
Chen, Z., Huang, A., Sun, J., Jiang, T., Qin, F. X.-F., & Wu, A. (2017) · Scientific Reports · doi:10.1038/srep40508 · Cited by 226
SuperTarget goes quantitative: update on drug-target interactions
Hecker, N., Ahmed, J., von Eichborn, J., Dunkel, M., Macha, K., Eckert, A., Gilson, M. K., Bourne, P. E., & Preissner, R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr912 · Cited by 213
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00014-x · Cited by 212
The cost of new drug discovery and development.
Dickson, M., & Gagnon, J. P. (2004) · PubMed · Cited by 186
Synergistic Drug Combination Prediction by Integrating Multiomics Data in Deep Learning Models
Zhang, T., Zhang, L., Payne, P. R. O., & Li, F. (2021) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0849-4_12 · Cited by 167
The neXtProt knowledgebase on human proteins: 2017 update
Gaudet, P., Michel, P.-A., Zahn-Zabal, M., Britan, A., Cusin, I., Domagalski, M., Duek, P. D., Gateau, A., Gleizes, A., Hinard, V., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1062 · Cited by 164
An update on Drug Repurposing: Re-written saga of the drug’s fate
GNS, H. S., GR, S., Murahari, M., & Krishnamurthy, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.127 · Cited by 161 · cited 1×
“[10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
MethodModern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
Landgren, O., & Iskander, K. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12590 · Cited by 160 · cited 1×
“For example, clinical trial data existing on adult individuals for the ‘morning sickness’ drug thalidomide contributed to its approval for multiple myeloma in 2012 at an estimated cost of only $40–80 million [4].”
MethodAssessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery
Bamborough, P., Drewry, D., Harper, G., Smith, G. K., & Schneider, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8011036 · Cited by 158
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-alawi, W., Safikhani, Z., & Haibe-Kains, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx911 · Cited by 155
Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · iScience · doi:10.1016/j.isci.2018.11.029 · Cited by 153 · cited 4×
“The data in these databases can be accessed, explored and visualized using the highly useful CellminerCDB portal [83].”
BackgroundMethodInfluentialCurrent status and new features of the Consensus Coding Sequence database
Farrell, C. M., O’Leary, N. A., Harte, R. A., Loveland, J. E., Wilming, L. G., Wallin, C., Diekhans, M., Barrell, D., Searle, S. M. J., Aken, B., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1059 · Cited by 145
GLIDA: GPCR ligand database for chemical genomics drug discovery database and tools update
Okuno, Y., Tamon, A., Yabuuchi, H., Niijima, S., Minowa, Y., Tonomura, K., Kunimoto, R., & Feng, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm948 · Cited by 144
Ursu, O., Holmes, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Stathias, V., Nguyen, D.-T., Schürer, S., & Oprea, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky963 · Cited by 142
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
van Dyck, C. H., Nygaard, H. B., Chen, K., Donohue, M. C., Raman, R., Rissman, R. A., Brewer, J. B., Koeppe, R. A., Chow, T. W., Rafii, M. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2050 · Cited by 142
PDBe: Protein Data Bank in Europe
Gutmanas, A., Alhroub, Y., Battle, G. M., Berrisford, J. M., Bochet, E., Conroy, M. J., Dana, J. M., Fernandez Montecelo, M. A., van Ginkel, G., Gore, S. P., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1180 · Cited by 142
Reversal of Baldness in Patient Receiving Minoxidil for Hypertension
Zappacosta, A. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012183032516 · Cited by 141
MPIDB: the microbial protein interaction database
Goll, J., Rajagopala, S. V., Shiau, S. C., Wu, H., Lamb, B. T., & Uetz, P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn285 · Cited by 139
GenomeRNAi: a database for cell-based and in vivo RNAi phenotypes, 2013 update
Schmidt, E. E., Pelz, O., Buhlmann, S., Kerr, G., Horn, T., & Boutros, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1170 · Cited by 139
ChemDB update—full-text search and virtual chemical space
Chen, J. H., Linstead, E. J., Swamidass, S. J., Wang, D. Y. Q., & Baldi, P. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm341 · Cited by 138
The Vertebrate Genome Annotation (Vega) database
Ashurst, J. L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki135 · Cited by 138
A novel heterogeneous network-based method for drug response prediction in cancer cell lines
Zhang, F., Wang, M., Xi, J., Yang, J., & Li, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21622-4 · Cited by 137
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Pardanani, A., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-01-0246 · Cited by 129 · cited 1×
“For example, Abl kinase-inhibitor imatinib has found use outside chronic myeloid leukaemia, as it also targets at least wild type c-Kit and PDGFR receptor tyrosine kinases within a well-tolerated clinical concentration range [125].”
BackgroundHodis, E., Prilusky, J., Martz, E., Silman, I., Moult, J., & Sussman, J. L. (2008) · Genome biology · doi:10.1186/gb-2008-9-8-r121 · Cited by 119
A review of the new HGNC gene family resource
Gray, K. A., Seal, R. L., Tweedie, S., Wright, M. W., & Bruford, E. A. (2016) · Human Genomics · doi:10.1186/s40246-016-0062-6 · Cited by 114
BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery
Dingerdissen, H. M., Torcivia-Rodriguez, J., Hu, Y., Chang, T.-C., Mazumder, R., & Kahsay, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx907 · Cited by 107
Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration
Wang, Z., Cao, S., Morris, J. S., Ahn, J., Liu, R., Tyekucheva, S., Gao, F., Li, B., Lü, W., Tang, X., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.028 · Cited by 96
DCDB: Drug combination database
Liu, Y., Hu, B., Fu, C., & Chen, X. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp697 · Cited by 95
Probes & Drugs portal: an interactive, open data resource for chemical biology
Škuta, C., Popr, M., Muller, T., Jindřich, J., Kahle, M., Sedlák, D., Svozil, D., & Bartůněk, P. (2017) · Nature Methods · doi:10.1038/nmeth.4365 · Cited by 90 · cited 1×
“[10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
MethodGPS-Prot: A web-based visualization platform for integrating host-pathogen interaction data
Fahey, M. E., Bennett, M. J., Mahon, C., Jäger, S., Pache, L., Kumar, D., Shapiro, A., Rao, K., Chanda, S. K., Craik, C. S., et al. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-298 · Cited by 87
Repurposing Drugs in Oncology: Next Steps
Verbaanderd, C., Meheus, L., Huys, I., & Pantziarka, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.06.007 · Cited by 85
Zhang, S.-D., & Gant, T. W. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-236 · Cited by 81
Orii, N., & Ganapathiraju, M. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049029 · Cited by 78
Setoain, J., Franch, M., Martínez, M., Tabas-Madrid, D., Sorzano, C. O. S., Bakker, A., Gonzalez-Couto, E., Elvira, J., & Pascual-Montano, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv445 · Cited by 76
Pyrvinium Attenuates Hedgehog Signaling Downstream of Smoothened
Li, B., Fei, D. L., Flaveny, C. A., Dahmane, N., Baubet, V., Wang, Z., Bai, F., Pei, X.-H., Rodriguez-Blanco, J., Hang, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0317 · Cited by 76 · cited 1×
“For example, anti-helminthic agent pyrvinium binds to and activates CK1α kinase, which has a net inhibitory effect on the Sonic Hedgehog pathway by virtue of CK1α acting as an endogenous antagonist for this pathway [129].”
BackgroundLevy, H., Wang, X., Kaldunski, M. L., Jia, S., Kramer, J., Pavletich, S. J., Reske, M., Gessel, T., Yassai, M. B., Quasney, M. W., et al. (2012) · Genes and Immunity · doi:10.1038/gene.2012.41 · Cited by 73 · cited 1×
“Some of the molecular alterations are conserved across patients, mutations, and specific conditions, and can be categorized as disease- or stateassociated/enriched (Table 2) [134, 135], which is the basis for drug connectivity mapping.”
BackgroundPatrick, M. T., Raja, K., Miller, K., Sotzen, J., Gudjonsson, J. E., Elder, J. T., & Tsoi, L. C. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.09.018 · Cited by 73
Tanoli, Z., Alam, Z., Vähä-Koskela, M., Ravikumar, B., Malyutina, A., Jaiswal, A., Tang, J., Wennerberg, K., & Aittokallio, T. (2018) · Database · doi:10.1093/database/bay083 · Cited by 71 · cited 5×
“We also highlight several new databases that have not been previously covered in any review (e.g. [10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
BackgroundMethodInfluentialSelf-citationIn silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
Mellini, M., Muzio, E. D., D’Angelo, F., Baldelli, V., Ferrillo, S., Visca, P., Leoni, L., Polticelli, F., & Rampioni, G. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02355 · Cited by 70 · cited 1×
“Similarly, virtual docking predicted inhibitory activity for five compounds from a collection of more than 1400 FDA-approved drugs against Pseudomonas aeruginosa quorumsensing (population-wide virulence) mechanisms, with antipsychotic agent pimozide displaying in vitro activity in inhibiting bacterial virulence gene e…”
BackgroundWeb-based drug repurposing tools: a survey
Sam, E., & Athri, P. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx125 · Cited by 69 · cited 1×
“[21] have presented web-based tools that can aid in repositioning of the drugs.”
MethodAssembly, Annotation, and Integration of UNIGENE Clusters into the Human Genome Draft
Zhuo, D., Zhao, W. D., Wright, F. A., Yang, H.-Y., Wang, J.-P., Sears, R., Baer, T., Kwon, D.-H., Gordon, D., Gibbs, S., et al. (2001) · Genome Research · doi:10.1101/gr.164501 · Cited by 61
Shaughnessy, A. F. (2011) · BMJ · doi:10.1136/bmj.d741 · Cited by 57 · cited 1×
“This has created opportunities to assess the potential for new drug uses even before the experimental testing, which has proven particularly attractive for orphan diseases, in which traditional drug development is limited [16, 17].”
BackgroundDong, W. G., Liu, C., Zheng, X., & Li, Y. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2608-9 · Cited by 56
Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
Joensuu, H. (2002) · PubMed · Cited by 53
The 26th annual Nucleic Acids Research database issue and Molecular Biology Database Collection
Rigden, D. J., & Fernández, X. M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1267 · Cited by 53 · cited 1×
“For instance, Nucleic Acids Research Database Issue contains information on more than 1700 unique databases and 64 new databases [25].”
BackgroundBreaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz006 · Cited by 50
Tanoli, Z., Alam, Z., Ianevski, A., Wennerberg, K., Vähä-Koskela, M. J. V., & Aittokallio, T. A. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby119 · Cited by 47 · cited 4×
“DTP is based on curated bioactivates whereas STITCH combines bioactivities with predicted compound target interactions using a weighted mechanism.”
BackgroundMethodInfluentialSelf-citationPathway-based subnetworks enable cross-disease biomarker discovery
Haider, S., Yao, C. Q., Sabine, V. S., Grzadkowski, M. R., Stimper, V., Starmans, M. H. W., Wang, J., Nguyen, F., Moon, N. C., Lin, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07021-3 · Cited by 43
Orthologue chemical space and its influence on target prediction
Mervin, L., Bulusu, K. C., Kalash, L. N., Afzal, A. M., Svensson, F., Firth, M. A., Barrett, I. P., Engkvist, O., & Bender, A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx525 · Cited by 42 · cited 1×
“Computational tools and machine learning facilitate drug structure-guided target prediction and repositioning Concomitant with experimental drug-target discovery efforts that provide quantitative molecular affinity data, computational tools are being built to predict/infer new molecular targets using orthogonal drug-t…”
BackgroundRepurposing available drugs for neurodevelopmental disorders: The fragile X experience
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R., Guilliams, T., & Cogram, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.004 · Cited by 39 · cited 1×
“As an example, the gene expression alterations triggered by three candidate compounds, disulfiram (Antabuse), metropolol, a beta1-receptor blocker used to treat high blood pressure, and nonsteroidal anti-inflammatory agent sulindac, were observed to match the gene expression patterns enriched in the neurocognitive dis…”
ResultRepurposing Thioridazine (TDZ) as an anti-inflammatory agent
Baig, M. S., Roy, A., Saqib, U., Rajpoot, S., Srivastava, M., Naim, A., Liu, D., Saluja, R., Faisal, S. M., Pan, Q., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30763-5 · Cited by 37 · cited 1×
“As an example of drug-target prediction based on molecular docking, antipsychotic agent thioridazine was found among 1500 FDA-approved compounds to possess anti-inflammatory activity by binding and inhibiting IKK, critical for the NF-κB pathway, which was also validated in experimental assays [143].”
BackgroundDrug response prediction by ensemble learning and drug-induced gene expression signatures
Tan, M., Özgül, O. F., Bardak, B., Ekşioğlu, I., & Sabuncuoğlu, S. (2018) · Genomics · doi:10.1016/j.ygeno.2018.07.002 · Cited by 35
Transcriptomic Data Mining and Repurposing for Computational Drug Discovery
Wang, Y., Yella, J., & Jegga, A. G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_5 · Cited by 32 · cited 1×
“Some of the molecular alterations are conserved across patients, mutations, and specific conditions, and can be categorized as disease- or stateassociated/enriched (Table 2) [134, 135], which is the basis for drug connectivity mapping.”
BackgroundAccurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes
Chi, X., Ai, D., Shi, D., Suo, S., Chen, X., Yan, Y., Cao, Y., Zhang, R., Sun, N., Chen, W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.031 · Cited by 31 · cited 2×
“As an example, the gene expression signatures of coding mutations across a large number of different cell types, called core transcriptomes, were filtered out from the gene expression changes triggered by the drugs to reveal the drugspecific, tissue-independent effects [137].”
BackgroundPhenotypic High-Throughput Screening Elucidates Target Pathway in Breast Cancer Stem Cell–Like Cells
Carmody, L., Germain, A. R., VerPlank, L., Nag, P. P., Muñoz, B., Perez, J. R., & Palmer, M. A. J. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112458317 · Cited by 30 · cited 1×
“Subsequently, the anti-cancer potency of ML239 was demonstrated to be reduced in the cells knocked out for FADS2 or simultaneously treated with FADS2 inhibitor [132, 133].”
BackgroundVigiAccess: Promoting public access to VigiBase
Shankar, P. R. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.190766 · Cited by 30
Legehar, A., Xhaard, H., & Ghemtio, L. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0141-7 · Cited by 25 · cited 2×
“We also highlight several new databases that have not been previously covered in any review (e.g. [10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
MethodIntegrating Biological Networks for Drug Target Prediction and Prioritization
Ji, X., Freudenberg, J., & Agarwal, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_12 · Cited by 20 · cited 1×
“Public data repositories are a considerable asset to drug development, but one of the biggest challenges of elevating drug repositioning to an informed and consistent parallel alternative to primary indication-oriented drug development has been mapping of the mechanisms of action and downstream interactions of the age…”
BackgroundTOPSAN: a collaborative annotation environment for structural genomics
Weekes, D., Krishna, S., Bakolitsa, C., Wilson, I. A., Godzik, A., & Wooley, J. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-426 · Cited by 18
Synergistic Drug Combination Prediction by Integrating Multi-omics Data in Deep Learning ModelsPreprint
Zhang, T., Zhang, L., Payne, P., et al. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1811.07054 · Cited by 18
GDA, a web-based tool for Genomics and Drugs integrated analysis
Caroli, J., Sorrentino, G., Forcato, M., Sal, G. D., & Bicciato, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky434 · Cited by 14 · cited 2×
“Transcriptomic and drug response data in databases, such as GDA, CCLE and GDSC, can be correlated to reveal drug mechanisms.”
MethodChen, Z., Huang, A., Sun, J., Jiang, T., Qin, F. X.-F., & Wu, A. (2017) · Scientific Reports · doi:10.1038/srep45416 · Cited by 8
In Vitro Models to Study the Regulatory Roles of Retinoids in Angiogenesis
Zen, A. A. H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9585-1_5 · Cited by 6
Research works printed but not linked: 1
- Lotfi Shahreza, 2018, A review of network-based approaches to drug repositioning, Brief Bioinform, 19, 878, 10.1093/bib/bbx017 · DOI · Paper page
Cited by
Use of molecular docking computational tools in drug discovery
(2021) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2021.01.004 · Cited by 621
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“27,28 More often, these techniques are synergistically utilized.”
MethodArtificial intelligence, machine learning, and drug repurposing in cancer
Tanoli, Z., Vähä-Koskela, M., & Aittokallio, T. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1883585 · Cited by 222
“Databases and other resources supporting insilico drug repurposing, such as Drug Repurposing Hub [9] and RepurposeDB [10], have also been recently surveyed [11].”
BackgroundMethodSelf-citationDeep learning for drug repurposing: Methods, databases, and applications
Pan, X., Lin, X., Cao, D., Zeng, X., Yu, P. S., He, L., Nussinov, R., & Cheng, F. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1597 · Cited by 188
“’s study.[22] Actually, deep learning is well suited to integrate heterogeneous data sources.”
BackgroundMethodA review on drug repurposing applicable to COVID-19
Dotolo, S., Marabotti, A., Facchiano, A., & Tagliaferri, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa288 · Cited by 181
Metadata
- Authors
- Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M.
- Affiliations
- University of Helsinki (FI)
- University of Copenhagen (DK)
- Corresponding author
- Tanoli, Ziaurrehman
- Tang, Jing
- Vähä-Koskela, Markus
- ORCID
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-14
- Volume
- 22
- Issue
- 2
- Pages
- 1656-1678
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- PMC
- PMC7986597
- OpenAlex
- W3006508031
- Semantic Scholar
- 31b64604c660c457f13b7adb6a3ac7baf643b9f7
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 22 · 2023: 25 · 2022: 25 · 2021: 17 · 2020: 10
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Briefings in Bioinformatics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- European Research Council (716063)
- Academy of Finland (317680)
- European Commission (824087)
- Medicinska Understödsföreningen Liv och Hälsa
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- drug repurposing, drug databases, database selection, molecular targets, drug mechanisms of action, adverse drug reactions, drug discovery
- MeSH terms
- Surveys and Questionnaires, Databases, Factual, Drug Delivery Systems, Computational Biology, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.